RT Journal Article
SR Electronic
T1 Clinical and functional connectivity outcomes of 5-Hz repeated transcranial magnetic stimulation as an add-on treatment in cocaine use disorder: a double-blind randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.15.20154708
DO 10.1101/2020.07.15.20154708
A1 Eduardo A. Garza-Villarreal
A1 Ruth Alcala-Lozano
A1 Sofia Fernandez-Lozano
A1 Erik Morelos-Santana
A1 Alan Dávalos
A1 Viviana Villicaña
A1 Sarael Alcauter
A1 F. Xavier Castellanos
A1 Jorge J. Gonzalez-Olvera
YR 2020
UL http://medrxiv.org/content/early/2020/07/19/2020.07.15.20154708.abstract
AB BACKGROUND Cocaine use disorder (CUD) is a global condition lacking effective treatment. Repeated magnetic transcranial stimulation (rTMS) may reduce craving and frequency of cocaine use, but little is known about its efficacy and neural effects.METHODS Using a double-blind placebo-controlled randomized clinical trial (RCT) [NCT02986438], we sought to elucidate short- and long-term clinical benefits of 5-Hz rTMS as an add-on to standard treatment in CUD patients and discern underlying functional connectivity effects using magnetic resonance imaging. Forty-four randomly assigned CUD patients completed the 2-week double-blind acute phase [Sham (n=20, 2f/18m) and Active (n=24, 4f/20m)], in which they received 2 daily sessions of rTMS (5,000 pulses) on the left dorsolateral prefrontal cortex. Subsequently, n=20 CUD patients continued to open-label maintenance (2 weekly sessions for up to 6 months). Measures were acquired at baseline, 2 weeks, 3 months and 6 months.RESULTS Overall, 5-Hz rTMS plus standard treatment for 2 weeks significantly reduced craving and impulsivity in the Active group; decreased impulsivity correlated with improvements in functional connectivity in executive control and default mode networks. Clinical and functional connectivity effects were maintained for 3 months but they dissipated by 6 months. We did not observe reduction of positive cocaine urine tests, however, self-reported frequency and grams consumed for 6 months were reduced.CONCLUSIONS With this RCT we show that 5-Hz rTMS has potential promise as an adjunctive treatment for CUD and merits further research.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT02986438Funding StatementThis study was supported by public funds CONACYT FOSISS No. 0260971 and CONACYT No. 253072. Student scholarships were provided by CONACYT for: Sofia Fernandez-Lozano No. 476284, Alan Davalos No.581492 and Erik Morelos-Santana No. 479345.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted at the Clinical Research Division of the National Institute of Psychiatry in Mexico City, Mexico, and all procedures were approved by the Institutional Ethics Research Committee (CEI/C/070/2016).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be freely available soon on Open Neuro, Neurovault and Zenodo.